| In millions, except per share items | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 | Mar-31-21 | Dec-31-20 |
| | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K |
| Operating activities | | | | | | | | |
| Net loss | -3.3 | -8.3 | -10.2 | -7.3 | -10.4 | -13.6 | -22.1 | -11.5 |
| |
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | | | |
| Depreciation and amortization | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Stock-based compensation | 1.5 | 1.4 | 1.3 | 1.4 | 1.4 | 1.2 | 1.2 | 0.6 |
| Non-cash interest expense | 0.2 | 0.2 | 0.2 | 0.3 | 0.3 | 0.3 | 0.1 | 0.2 |
| Non-cash change in fair value of PIPE Warrant liability | | | | | | -2.6 | 2.4 | -1.7 |
| Amortization of premium and discount on investments | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | | 0.0 |
| Changes in operating assets and liabilities: | | | | | | | | |
| Trade receivables, net | -3.4 | -2.3 | -3.1 | -1.5 | -4.1 | -3.1 | -1.1 | |
| Partnership receivables | -0.2 | 0.0 | 1.0 | -0.6 | 0.2 | 0.1 | -0.2 | -0.1 |
| Inventory | 0.2 | 0.4 | 0.0 | -0.4 | -1.3 | | | |
| Prepaid expenses and other current assets | 0.5 | 0.2 | 0.9 | -1.0 | 0.0 | -1.2 | 0.5 | -0.8 |
| Operating lease right-of-use asset | 0.0 | -0.1 | 0.1 | 0.5 | 0.1 | 0.1 | 0.1 | 0.1 |
| Other non-current assets | 0.0 | | | | | | -0.1 | |
| Accounts payable | 1.4 | 0.6 | 0.3 | -2.2 | 1.8 | -0.8 | 0.6 | 1.4 |
| Accrued clinical trial costs and contract manufacturing | 5.5 | | | | 2.0 | | | |
| Accrued compensation and benefits | 1.5 | 0.8 | -1.5 | | 0.7 | 1.8 | -1.4 | |
| Other accrued liabilities | 1.6 | 1.0 | 1.6 | -1.0 | 2.0 | 0.3 | 1.7 | -0.7 |
| Operating lease liability | 0.0 | 0.0 | 0.0 | -0.4 | 0.0 | 0.0 | 0.0 | -0.1 |
| Deferred revenue | | | -0.6 | -0.5 | -0.5 | -0.5 | -0.5 | -0.5 |
| Deferred research and development reimbursements | | | | | 0.0 | -0.1 | -0.1 | -0.1 |
| Operating lease liability, non-current | | | | 0.0 | -0.1 | -0.1 | -0.1 | 0.0 |
| Net cash used in operating activities | 0.2 | -2.5 | -8.2 | -12.2 | -8.1 | -18.7 | -18.3 | -12.9 |
| |
| Investing activities | | | | | | | | |
| Purchases of marketable securities | | -6.0 | -3.0 | 0.0 | 0.1 | -28.2 | | |
| Proceeds from maturities and sales of marketable securities | 7.0 | 4.2 | 14.5 | 8.4 | 2.9 | | | 29.0 |
| Net cash provided by (used in) investing activities | 7.0 | -1.8 | 11.5 | 8.4 | 3.0 | -28.2 | | 28.9 |
| |
| Financing activities | | | | | | | | |
| Proceeds from issuance of common stock, net of issuance costs | | | | | | 0.1 | 55.0 | 5.9 |
| Proceeds from warrant exercises | | | | | | | 3.1 | |
| Proceeds from issuance of stock for stock-based compensation arrangements | 0.0 | 0.6 | | 0.5 | | 0.1 | | 0.0 |
| Proceeds from issuance of loan payable | | | | 5.0 | | | 20.0 | |
| |
| Payment of loan maturity fees (Note 6) | | | | | | | | |
| Payment of debt issuance costs | | | | | | | -0.1 | |
| Net cash provided by financing activities | 0.0 | 0.6 | | 5.5 | -0.8 | 0.2 | 78.0 | 5.9 |
| Net increase in cash and cash equivalents | 6.9 | | | | 7.1 | | | |
| |
| Supplemental cash flow information | | | | | | | | |
| Cash paid for interest | 1.2 | 1.0 | 0.9 | 0.9 | 0.9 | 0.8 | 0.4 | 0.4 |